orphan drug status
Iressa Approval Grows Options for Lung Cancer Patients as AstraZeneca Re-establishes Presence
Premium
Non-small cell lung cancer patients with EGFR mutations now have three treatment choices, and AstraZeneca is working on newer personalized treatment options.
Pelago Bioscience, OmicScouts Collaborate on Proteomics for Drug Discovery
Pelago will license its cellular thermal shift assay technology to OmicScouts and the firms will collaborate to offer drug target identification and validation.
With Latest Orphan Status for Entrectinib in CRC, Ignyta Continues to Pursue Precision Rx Approach
Premium
Entrectinib is Ignyta's lead product that the biotech is investigating in patients with tumors characterized by TrkA, TrkB, TrkC, ROS1, and ALK markers.
Alnylam Pharmaceuticals said this week that the US Food and Drug Administration has given orphan drug status to the company's investigational transthyretin-mediated amyloidosis ALN-TTR02 as a treatment for familial amyloidotic polyneuropathy, a common manifestation of the disease
Specifically, the designation is for the use of the drug against familial amyloidotic polyneuropathy, one of the predominant forms of the disease, Alnylam said.
Jun 17, 2010
Feb 18, 2010